EMBR-22. RATIONAL DEVELOPMENT OF SYNERGISTIC THERAPIES ALONGSIDE BMI1 INHIBITION FOR GROUP 3 MEDULLOBLASTOMA

Medulloblastoma (MB) is the most common pediatric brain tumor. Of its four distinct molecular subgroups, Group 3 MBs are associated with increased risk of recurrence, metastasis and overall poor patient outcome. In recent years, small molecule inhibitors targeting BMI1 have shown to be efficacious a...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Bakhshinyan, David, Adile, Ashley A, Venugopal, Chitra, Brown, Kevin, Chan, Katherine, Qazi, Maleeha A, Chokshi, Chirayu, Gwynne, William D, Tieu, David, Moffat, Jason, Singh, Sheila
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2021
Konular:
Embryonal Tumors
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8168109/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noab090.040
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller